Variables | Â | Univariate | Â | Â | Multivariate | Â |
---|---|---|---|---|---|---|
 | OR | 95% CI | P | OR | 95% CI | P |
Sex | Â | Â | 0.100 | Â | Â | 0.092 |
 Male | 1.00 |  |  | 1.00 |  |  |
 Female | 2.42 | (0.85–6.93) |  | 3.40 | (0.82–14.15) |  |
Age (years) | 1.01 | (0.96–1.07) | 0.633 |  |  |  |
Time from diagnosis to ART (months) | 0.98 | (0.94–1.01) | 0.183 |  |  |  |
Transmission route | Â | Â | 0.857 | Â | Â | Â |
 Homosexual | 1.00 |  |  |  |  |  |
 Heterosexual | 1.36 | (0.44–4.27) |  |  |  |  |
 Others | 1.42 | (0.20–9.82) |  |  |  |  |
HIV-1 subtype | Â | Â | 0.717 | Â | Â | Â |
 AE | 1.00 |  |  |  |  |  |
 B/C/BC | 1.48 | (0.37–5.96) | 0.584 |  |  |  |
 Others | 1.68 | (0.48–5.95) | 0.418 |  |  |  |
ART therapy | Â | Â | 0.477 | Â | Â | Â |
 AZT/d4T + 3TC + NVP | 1.00 |  |  |  |  |  |
 TDF + 3TC + EFV | 0.67 | (0.22–2.04) |  |  |  |  |
Plasma viral load at enrollment (log copies/mL) | 0.71 | (0.36–1.41) | 0.330 |  |  |  |
HIV-1 DNA at enrollment (log copies/106 PBMCs) | 0.72 | (0.17–3.11) | 0.656 |  |  |  |
CD4+ T-cell count at enrollment (cells/μL) | 1.00 | (1.00–1.01) | 0.134 |  |  |  |
Nadir CD4+ T-cell count (cells/μL) | 1.00 | (1.00–1.01) | 0.129 |  |  |  |
CD8+ T-cell count at enrollment (cells/μL) | 1.00 | (1.00–1.00) | 0.528 |  |  |  |
CD4/CD8 ratio at enrollment | 1.19 | (0.95–1.48) | 0.124 |  |  |  |
Plasma viral load at week 96 | Â | Â | 0.808 | Â | Â | Â |
 Undetectable | 1.00 |  |  |  |  |  |
 Viremia | 0.75 | (0.07–7.66) |  |  |  |  |
CD4+ T-cell count at week 96 (cells/μL) | 1.00 | (1.00–1.00) | 0.709 |  |  |  |
CD8+ T-cell count at week 96 (cells/μL) | 0.99 | (0.99–0.99)a | 0.018 | 1.00 | (0.99–1.00) | 0.462 |
CD4/CD8 ratio at week 96 (per 0.1 increase) | 1.28 | (1.05–1.55) | 0.014 | 1.29 | (1.05–1.59) | 0.017 |